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Abstract
X-ray absorption spectroscopy (XAS), including Extended X-ray Absorption Fine Structure 
(EXAFS) and XANES (X-ray Absorption Near Edge Structure), has been carried out at the Zn K 
edge of the N-terminal part of the integrase protein of the Human Immunodeficiency Virus, type 2 
(HIV-2), and of some zinc coordination compounds. In the presence of excess P-mercaptoethanol, 
which was present in the NMR structure elucidation of the protein (Eijkelenboom et al. (1997) 
Current Biol. 7, 739-746; Eijkelenboom et al. (2000) J. Biomol. NMR 18, 119-28), the protein 
spectrum was nearly identical to that recorded in its absence. Comparison of the XANES of the 
protein to that of model compounds and literature data permits the conclusion that the Zn ion is 
four-coordinated. The major shell of the EXAFS gives evidence for a mixed (N or O as well as S) 
coordination sphere, while the minor shells indicate imidazole coordination. Our approach to the 
analysis of the EXAFS, including quantification of the imidazole by multiple scattering simulations 
with EXCURV92, was validated on the model compounds. An important result is that with 
multiple scattering simulations using restraints on the parameters of the imidazole rings, the 
number of imidazoles as well as their orientation could be determined. The integrase spectra can be 
fitted with 2 sulfur ligands at 2.26 A (Debye-Waller-type factor 0.009 A2) and 2 imidazole ligands 
with the nitrogens at 1.99 A (Debye-Waller-type factor 0.005 A2). The XAS-derived geometry is 
fully consistent with that found in the NMR structure determination and, allowing for the volume 
contraction due to the temperature difference between the experiments, justifies the restraints 
applied in the structure calculation (Zn-S and Zn-N distances of 2.3 and 2.0 A, respectively).
Introduction
Integration of a DNA copy of the viral RNA into the genome of the infected cell is an 
important step in the infectivity cycle of the human immunodeficiency virus (HIV). This 
integration process is catalysed by the viral enzyme integrase (for reviews see Brown, 1997; 
Hansen et al., 1998). Integrase (IN) can be split by partial proteolysis in three functional domains 
that are amenable to structure elucidation by X-ray crystallography and high-resolution 2D and 3D 
NMR techniques. In the last years, structures of mutants of the catalytic core (X-ray 
crystallography, Dyda et al., 1994; Goldgur et al., 1998; Maignan et al., 1998; Greenwald et al.,
1999) and of the C-terminal DNA binding domain (NMR, Eijkelenboom et al., 1995; Lodi et al., 
1995; Eijkelenboom et al., 1999) of HIV-1 integrase have been reported. Recently, a crystal 
structure of an HIV-1 IN fragment containing both the catalytic core and the C-terminal domain has 
been solved (Chen et al., 2000). The N-terminal (55 amino acids) part of HIV integrase contains a 
Zn binding HHCC (HisX3 HisX2 3 CysX2 Cys) motif, which does not show homology with classical
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zinc-finger sequences (Klug & Rhodes, 1987; Kaptein, 1991; Berg & Shi, 1996). The NMR 
structures of this domain of HIV-1 integrase (Cai et al., 1997) and of HIV-2 integrase 
(Eijkelenboom et al., 1997; Eijkelenboom et al., 2000) have been determined by high resolution 2D 
and 3D NMR techniques. Interestingly, in the course of this determination, the three-dimensional 
structure turned out to be a novel fold for a zinc-binding protein. Therefore, the need was felt for an 
independent determination of the Zn coordination; in addition, this would be an opportunity to 
probe the effect of the non-physiological reductant P-mercaptoethanol, which was present in the 
NMR samples.
Zn proteins are accessible by few spectroscopic techniques and their study by X-ray 
absorption spectroscopy is well-documented (Cramer, 1988; Feiters et al., 1986; Garner & Feiters, 
1987; Hasnain & Garner, 1987; Feiters, 1990; Clark-Baldwin et al., 1998). There are various 
studies of zinc-finger type proteins (Diakun et al., 1986; Summers et al., 1992) and recent 
examples of Zn XAS studies include carbonic anhydrase (Bracey et al., 1994; Alber et al., 1999), 
metallothionein (Jiang et al., 1994) and the related neuronal growth inhibitory factor (Bogumil et 
al., 1998), methionine synthase (González et al., 1996; Peariso et al., 1998; Zhou et al., 1999), 
other methyl transferases (Gencic et al., 2001; Krüer et al., 2002), and Zn-containing ferredoxin 
(Cosper et al., 1999). The XANES (X-ray Absorption Near Edge Structure) part of the spectrum 
gives information on valence state and coordination geometry, while the Extended X-ray 
Absorption Fine Structure (EXAFS) part provides ligand distances and coordination numbers with 
relatively high (± 0.02 Á) and low (± 20 %) accuracy, respectively. Furthermore, the phase 
relationship between EXAFS and its Fourier transform together with the amplitude envelope of the 
EXAFS permit determination of the type of ligand Z (accuracy ± 1). As the coordination geometry 
derived from XANES is related to the coordination number provided (with low accuracy) by 
EXAFS, e.g. tetrahedral geometry with 4-coordination, and octahedral geometry with 6- 
coordination, the two parts of the spectrum are considered to give complimentary information.
Because of its potential to discriminate between coordination of S or low-Z (C, N, O) 
ligands, it has been proposed that EXAFS can be used to classify zinc sites according to ligand 
environment (Garner & Feiters, 1987; Hasnain & Garner, 1987; Feiters, 1990, Table 1), viz. type A 
sites with only S ligands (like the ‘structural’ site in liver alcohol dehydrogenase, Eklund et al., 
1976, Eklund & Brandén, 1983), type B with mixed (S as well as N or O) ligation (e.g. the 
‘catalytic’ site of liver alcohol dehydrogenase), and type C with only N/O ligands (with carbonic 
anhydrase (Liljas et al., 1972), thermolysin (Colman et al., 1972) and superoxide dismutase 
(Richardson et al., 1975) as early examples). Because of the association with the LADH sites it is 
tempting to consider type B (and C) sites as catalytically active zinc, and type A as only structural
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zinc (Garner & Feiters, 1987); the lower number of S ligands when going from type A via type B to 
type C sites would account for increasing Lewis acidity of the zinc and hence mean more catalytic 
power. However, the type C site in superoxide dismutase (Richardson et al., 1975; Blackburn et al., 
1983; Murphy et al., 1996) nor the type B sites in e.g. transcription factors have catalytic activity, 
and in the current mechanism of purple acid phosphatase (Klabunde et al., 1996), the type C zinc in 
the heterodinuclear Fe, Zn site in that enzyme only acts as a phosphate binding site while hydroxide 
anion is activated for nucleophilic attack on the nearby iron ion. Moreover, recent structural and 
mechanistic studies on cobalamin-independent methione synthase (González et al., 1996; Peariso et 
al., 1998; Zhou et al., 1999) have revealed the power of Zn(II) ions with negatively charged 
ligands, including both carboxylates and thiolates, to increase the nucleophilicity of thiol. As to the 
potential of EXAFS to classify Zn sites, recent fundamental work (Clark-Baldwin et al., 1998) has 
shown that care has to be taken with the possible false-positive identification of low numbers of the 
relatively weak low-Z (C, N, O) scatterers in the presence of larger numbers of sulfurs.
The accuracy of the distance information can be of help in the refinement of metal sites in 
crystal structures of metalloproteins to subatomic resolution (Hasnain & Hodgson, 1999), and this 
notion will undoubtedly link X-ray absorption spectroscopy of metalloproteins very strongly to X- 
ray diffraction. Nevertheless, it is expected that the independent determination of metal 
environments by EXAFS, as well as its use to complement information obtained from other than 
crystallographic sources, like computer predictions based on amino acid sequences and structures 
obtained from high-resolution 2D and/or 3D NMR studies, will continue to be important. In the 
past we have given an example of an EXAFS study on sheep liver sorbitol dehydrogenase (Feiters 
& Jeffery, 1989) to compliment a structure prediction (Eklund et al., 1985) based on alignment of 
the amino acid sequence to the largely homologous horse liver alcohol dehydrogenase, for which 
the crystal structure was known (Eklund et al., 1976, Eklund & Brandén, 1983). Comparison of the 
sorbitol dehydrogenase Zn EXAFS (Feiters & Jeffery, 1989) to that of a transcription factor 
(Diakun et al., 1986) as well as independent simulation of the data corroborated the proposal that 
compared to the catalytic Zn site in liver alcohol dehydrogenase, one of the sulfur ligands to Zn is 
replaced by a low-Z ligand in sorbitol dehydrogenase.
The present paper deals with an EXAFS study carried out to complement an alternative 
structure determination, i.e. by high-resolution NMR, as well as with the development of protocols 
for EXAFS analysis which are checked on model compounds.
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Experimental
Protein purification and sample preparation. The production and purification of the 55- 
residue N-terminal domain of HIV-2 integrase was performed as described previously 
(Eijkelenboom et al., 1997). The obtained lyophilized protein was dissolved in 175 ^l H2O with 1.1 
molar equivalent of ZnCl2 either in the presence or absence of 2 mM P-mercaptoethanol, and the 
pH was adjusted to 6.6. The final protein concentration was in the range 4-5 mM.
EXAFS measurements. EXAFS measurements at the Zn K edge were carried out in the 
European Molecular Biology Laboratory (EMBL) Outstation in the Hamburg Synchrotron 
Laboratory (HASYLAB) at the Deutsches Synchrotron (DESY) in Hamburg, Germany. During 
data collection, the storage ring DORIS III was operated at 4.5 GeV in the dedicated mode with 
ring currents between 80 and 40 mA. The EXAFS station features an order sorting monochromator, 
which was set at 50 % of peak intensity to suppress harmonics (Hermes et al., 1984), a 
CANBERRA 13 element solid-state fluorescence detector, and an energy calibration device 
(Pettifer & Hermes, 1985). Typically 20 scans per sample were taken. The sample was kept at 20 K 
during the measurements and moved in between scans so that the part of the sample that was 
exposed to the beam was varied as much as possible. No spectroscopic differences between scans 
were observed. The preparation and measurements of the Zn model compounds 1-5 (cf. Chart 1 for 
schematic structures) were described earlier (Eggers-Borkenstein et al., 1989).
EXAFS data reduction and analysis. Data reduction was carried out at the EMBL and at 
the CAOS-CAMM Center, University of Nijmegen, with the EMBL Outstation data reduction 
package (Nolting & Hermes, 1992) inluding the energy calibration programmes CALIB and 
ROTAX, the averaging programme MEAN, and the background subtraction programme 
EXTRACT. Simulations of the calibrated, averaged, and background-subtracted EXAFS were 
carried out on the CLRC Daresbury Laboratory (Warrington, UK) dedicated EXAFS computer 
using the EXAFS simulation progamme EXCURV92 (Gurman et al., 1984, 1986; Binsted et al., 
1991), including the programme MUFPOT for the ab initio calculation of phase shift and 
backscattering factors. Model compound crystallographic coordinates were retrieved from the 
Cambridge Crystallographic Data Base. Tables of distances to Zn and angles were obtained with 
the programme XTAFS (courtesy of R. de Gelder) for compounds 1, 3, 4, and 5, whereas data for 2 
were taken directly from the literature (Klug, 1966).
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Results and Discussion
In Figure 1, the XANES (Fig. 1a), k3-weighted EXAFS (Fig. 1b), and phase-corrected 
Fourier transform (Fig. 1c) of the integrase in presence and absence of P-mercaptoethanol are 
compared to a number of model compounds (Eggers-Borkenstein et al., 1989; Eggers-Borkenstein, 
1989) which have been shown by crystallography to have four-coordinated zinc, viz. zinc(II) 
ethylxanthate (1, Ikeda & Hagihara, 1966), zinc(II) dimethyldithiocarbamate (2, Klug, 1966), 
tetrakis(imidazole)zinc(II) diperchlorate ([Zn(im)4](ClO4)2, 3, Bear et al., 1975), and 
zinc(II)(imidazole)2(acetate)2 ((Zn(im)2(acetate)2, 4, Horrocks et al., 1982). The XANES (Fig. 1a) 
of the integrase data resembles the model compounds shown in some aspects, viz. the presence of 
multiple edge features and the relatively low intensity (normalized edge step < 1.5). It is different 
from that of other model compounds (Eggers-Borkenstein et al., 1989; Eggers-Borkenstein, 1989) 
which have strong ‘white lines’ resulting in typical normalized edge steps > 1.5 and even > 2 for 
five- and six-coordinated zinc, respectively (not shown). The XANES spectra therefore indicate 
that the zinc ion in the N-terminal part of HIV-2 integrase is four-coordinated. The presence of P- 
mercaptoethanol did not have much influence on this part of the spectrum. For Cu(I) and Cu(II) 
ions, XANES features can be explained by electronic transitions, (Kau et al., 1987) but for the 
Zn(II) ion this is not straightforward as the 3d shell is completely filled with electrons. In recent 
years approaches have been developed to simulate the XANES region of the X-ray absorption 
spectra by analysing the multiple scattering of electron waves between all atoms (intra- as well as 
inter-ligand scattering) around the absorber, (Della Longa et al., 1995; de Groot, 2001; Benfatto & 
Della Longa, 2001) but an exploration of these approaches is outside the scope of this paper.
In the Fourier transform of the EXAFS, taken over the full measured energy range (0-980 
eV, 2 A-1<k<16 A-1) to enhance the resolution in the radial distribution function (Fig.2, Clark- 
Baldwin et al., 1998), we observe a major peak at approx. 2.0-2.3 A which shows clear evidence of 
its mixed character with N and S contributions at 2.0 and 2.3 A, respectively, and relative 
intensities which are in agreement with equivalent numbers of N and S ligands when the difference 
in backscattering amplitude (Feiters et al., 1990) is taken into account. Minor shells at 3 and 4 A 
are also observed which give evidence for imidazole coordination. There is a small but significant 
effect of P-mercaptoethanol on the integrase Zn EXAFS (Fig.2), viz. at high k (9-16 A-1) but also at 
5 A-1 in the EXAFS, and in the 'S' peak and the 3 A imidazole C peak in the Fourier transform. 
These differences, however, are not found to correspond to major changes in the coordination, as 
the analysis (see below) shows that the data can be simulated with the same parameters, requiring 
only small adjustments of some of the Debye-Waller-type factors.
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Analysis of the EXAFS started with phaseshift calculations by the MUFPOT subroutine of 
the simulation programme EXCURV92 (Binsted et al., 1991). It had been shown previously 
(Eggers-Borkenstein et al., 1989) that the major shells of the data could be satisfactorily analysed 
with either empirical or theoretical (McKale et al., 1988) amplitude and phase functions. For the 
present simulations, however, we chose EXCURVE because of the possibility to simulate and 
iteratively refine the multiple scattering of imidazole rings with restraints (Binsted et al., 1992), and 
because of the successful earlier application (EXCURV88, Forster et al., 1996) in the simulation of 
Zn imidazole EXAFS spectra. The results of the present calculations were tested on the model 
compounds zinc(II) ethylxanthate 1 and tetrakis(imidazole)zinc(II) diperchlorate 3, which feature 
Zn-sulfur (Ikeda & Hagihara, 1966) and -imidazole (Bear et al., 1975) coordination, respectively. 
In line with the results of earlier studies on Cu-pyridine complexes (Feiters et al., 1999), the 
iteratively refined simulations with phaseshifts calculated with the exchange potential and the 
ground state set to 'Xa' were preferred to those calculated with the Hedin-Lindqvist/von Bart 
settings, as resulting parameters gave better agreement with the crystallographic values. The 
contribution of the imidazole group was simulated with multiple scattering (Strange et al., 1986, 
1987; Pettifer et al., 1986; Feiters et al., 1988), and the distance, occupancy, angle and threshold 
energy values were iteratively refined with the interatomic distances of the imidazole ring as 
derived from the crystal structure of 3 (Fig. 3, Bear et al., 1975) as a restraint (Binsted et al., 1992). 
Optimum agreement for the coordination numbers for both model compounds was obtained with 
the amplitude reduction factor (AFAC) set to 0.75, which led to 3.9 sulfurs at 2.33 A for 1, and 4.4 
imidazoles at 1.97 A for 3, which is in excellent agreement with the crystallographic values of 4 at 
2.36 and 4 at 2.00 A, respectively, considering the possibility of a slight volume contraction due to 
the lower temperature of the EXAFS measurements. In the final simulations for the Zn-sulfur 
model compounds 1 and 2, contributions for the minor shells were also included, and AE0, 
distances, occupancies, and Debye-Waller-type factors were iteratively refined. For inclusion of 
each additional shell to be justified, it was required that the fit index was lowered by more than 5 % 
(Joyner et al., 1987). As can be seen in Fig. 4 and Table 2, the agreement between EXAFS and 
crystallography was excellent for the major shells (agreement in occupancy <10 %, distances 
underestimated by only ± 0.02 A). The results for the minor shells have to be considered as no 
more than a qualitative indication that certain types of atoms are present at a certain distance, 
because the agreement for the distances was reasonable (± 0.05 A for 1, ± 0.1 A for 2), whereas that 
for the occupancies was disappointing.
In the case of the imidazole compounds 3, 4, and di-(L-histidino)-zinc(II) dihydrate 
([Zn(his)2](H2O)2, 5, Kretsinger et al., 1963) (Fig. 5, Table 3), the multiple scattering was essential 
for the reproduction of the characteristic spectral features with crystallographically reasonable
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parameters, in particular of the ‘camel back’ feature at 4-5 A 1 (Bordas et a l, 1983) which is 
strongest for 3. It is of interest to inspect the final geometries of the imidazole rings after 
refinement, which are displayed as insets in the bottom panels of Fig. 5, and to check the final 
parameters against the crystallographic values in Table 3. In initial refinements, applying the 
‘single’ (bold) restraints from Fig. 3, the Debye-Waller-type factors were allowed to float in order 
to obtain a reasonable estimate for their values. The values obtained for the carbon contributions at 
approx. 3 A were then averaged and used in further refinements, so that they would remain the 
same for both carbons; the same procedure was followed for the carbon and nitrogens at just above 
4 A. In spite of the restraints applied, this approach resulted in a slight distortion of the geometry of 
the imidazole unit as judged from the distances to zinc (Fig. 5a, Table 3). However, the deviations 
in the angles were relatively small (< 2 degrees) and it can be concluded that the ‘symmetric’ 
coordination of the imidazole ring with respect to the Zn-N vector (i.e. small differences between 
angles with respect to Zn-N for equivalent contributions, viz. -126.03/+126.01 for the carbons at 
approx. 3 A, and -161.54/+161.63 for the carbon/nitrogen at just above 4 A) which is found in the 
crystal structure, is reproduced in the analysis of the EXAFS data. It is interesting to note that the 
symmetry of each individual imidazole unit and the similarity between the imidazole moieties are 
much larger in the room-temperature crystal structure of 3 (Bear et al., 1975) than in another well- 
studied metal imidazole complexes with non-coordinating counterions, viz. [Cu(imidazole)4 ] 
(perchlorate)2 (Ivarson, 1973) and [Cu(imidazole)4] (nitrate)2 (MacFadden et al., 1976), but that the 
higher order is not reflected in significant narrowing of the corresponding EXAFS signals (Strange 
et al. 1987; Feiters et al., 1988); this probably means that the asymmetry/disorder present in the Cu 
complexes at room temperature is decreased at lower temperatures.
For both other Zn imidazole complexes the crystal structures (Horrocks et al., 1982; 
Kretsinger et al., 1963) show that significant deviations from symmetry around the Zn-N vector 
exist, and with the approach outlined above for the simulation of the EXAFS, the different angles 
are reproduced to within 3 degrees for 4, and 7 degrees for 5 (Fig. 5b-c; Table 3). For compound 4, 
the difference in the distances from Zn to the carbons at approx. 3 A is so large (2.93 vs. 3.08 A) 
that the corresponding EXAFS waves interfere destructively so as to virtually wipe out their 
contribution to the Fourier transform (Fig. 5b, bottom panel). The EXAFS result (Table 3) that the 
non-imidazole ligands in both systems coordinated at shorter (acetate oxygens in 4) and longer 
(amino nitrogens in 5) distance, respectively, is also in agreement with the respective crystal 
structures, although the deviations (0.03 A for 4, 0.05 A for 5) are a little larger than is typical for 
first shell contributions. In this context it is of interest to consider the fitting errors (given by 
EXCURV92 as 2a when the fit index in the refinement approaches a minimum) although this is 
difficult in view of the application of restraints in the refinement. For our simulations of 3, the
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fitting error for the main shell distance is much smaller than the other errors leading to deviations 
from crystallographic values, like inaccuracies in the phaseshift calculations, in agreement with the 
analysis of [Cu(imidazole)4] (nitrate)2 (Binsted et al., 1992). For the simulations of 4 and 5, 
however, the fitting errors for the mains shell distances were much larger and are the main factor 
contributing to deviations from crystallographic values. The larger fitting errors for the simulations 
of compounds 4 and 5 as compared to 3 are due to the correlations between the two independent 
contributions to the main shell (imidazole nitrogens together with acetate oxygens for 4, and 
imidazole nitrogens together with amine nitrogens for 5) and to the lack of freedom for the distance 
parameters to move in the direction given by the decreasing fit index because of the restraints 
imposed by the geometry of the imidazole ring. We have confidence in the outcome of the 
restrained refinement in spite of the relatively large fitting errors, because of the correct analysis of 
both the relative distances of imidazole and non-imidazole contribution as well as the geometry of 
the imidazole ring, and note that even an error of 0.05 A in a first shell distance means that the 
EXAFS result is still a valuable contribution toward improving the resolution of a protein structure 
determined by NMR or single crystal X-ray diffraction. The success in correctly analysing the 
relative order of the distances to Zn in spite of the fact that the contributions are not resolved is due 
to the use of the distance information contained in the minor shells for the imidazole, together with 
the multiple scattering analysis and the application of the restraints, and offers some hope for 
discrimination in future metalloprotein studies between N(imidazole) ligands on the one side, and 
oxygen and non-imidazole nitrogen ligands on the other.
Simulations of the integrase EXAFS confirmed the presence of both nitrogen (imidazole) 
and sulfur contributions. In order to avoid problems with possible artefacts at high k, the integrase 
EXAFS was analyzed over energy ranges of 2.63 - 735 eV and 2.63 -  700 eV for the spectra with 
and without P-mercaptoethanol, respectively. With the intra-ligand multiple scattering included it 
was hoped that the low energy part of the spectrum would be adequately simulated. The fact that 
slight discrepancies were noted (cf. the low-k region of the top panels in Fig. 6) indicates that inter­
ligand scattering also contributes to the X-ray absorption spectrum in this system. No attempts were 
made to simulate this feature. Distances, threshold energy, Debye-Waller-type factors and angles 
were refined with the optimum geometry of the imidazole ring as a restraint (cf. Fig. 3) and 
occupancies were varied in steps between 1-4 N (imidazole) ligands and 1-4 S ligands. For the 
integrase EXAFS in the presence of P-mercaptoethanol, the combination of 2 nitrogen (imidazole) 
and 2 sulfur ligands clearly stood out as the possibility with the lowest fit index (Table 5). For the 
integrase EXAFS recorded in the absence of P-mercaptoethanol, the coordination numbers 
appeared to be less well defined and equally good fit indices were obtained with the 2N + 2S, 2N + 
3S, 3N + 2S, and 3N + 3S combinations (Table 5). Of all the possibilities, however, with a total
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coordination number of 4, which was indicated by the comparison of the XANES to that of model 
compounds (see above), the 2N + 2S combination was clearly the best (Table 5), and in the 
simulations with 3 imidazole ligands the Debye-Waller-type factors of the outer shells, i.e. those at 
3-4 A, refined to unrealistically high values. The final fits for the integrase spectra are presented in 
Fig. 6; the parameters are in Table 4. It should be noted that the problem of high fitting errors for 
combinations of contributions to the main shell as noted for compound 4 (imidazole nitrogen and 
acetate oxygen) and compound 5 (imidazole and amine nitrogen) and high correlations between 
them does not exist for the combination of imidazole nitrogen and sulfur, probably because the 
contributions are different in phase and sufficiently resolved in distance. As mentioned above there 
is a small but significant effect of P-mercaptoethanol on the spectrum. In the refinement of the 
simulations, however, the only parameter that was significantly affected by the presence of P- 
mercaptoethanol was the Debye-Waller-type factor for S which decreased from 0.009 to 0.007. 
This possibly means that a small fraction of the excess Zn is present in a complex with P- 
mercaptoethanol, a possibility which does not affect the validity of the NMR structure 
determination. In the final fits (Fig. 6, Table 4) the coordination of the imidazole residues to the Zn 
was totally symmetric.
In the NMR structure (Eijkelenboom et a l, 1997) it was noted that one of the imidazole 
coordinates with the e-nitrogen, the other with the 8-nitrogen (Fig. 7). In the latter case, the 
methylene of the histidine side chain might be expected to be detectable by EXAFS as it would be 
positioned at a distance of approx. 3.5 A to the Zn. Attempts were made to get independent 
evidence for this feature from analysis of the EXAFS. A shell of additional carbon when included 
in the simulation of both integrase EXAFS spectra refined to a distance of 3.6 A but did not lead to 
a decrease in the fit index that would be sufficiently statistically significant (5 %, Joyner et al., 
1987) to justify its inclusion. In a comparative study of metal complexes of methyl-substituted and 
unsubstituted imidazoles (Feiters et al., 1988), it was already noted that all imidazole EXAFS 
spectra show features at 3.5 A, regardless of the presence of the methyl substituent.
The effect of additional Zn atoms at the outer limit of detectability in the radial distribution 
function obtained by Fourier transformation of the EXAFS (approx. 4.5 A) was also investigated, 
as possible evidence for dimerization of the integrase N-terminal part, but this did not improve the 
quality of the simulation either; in any case, even in case of dimerization of the integrase the Zn 
atoms would not have been able to approach eachother to such a close distance. The question of 
possible false-positive identification of metal-metal distances is of wider significance in the area of 
zinc enzymes, in particular in view of the discrepancy that has been noted between the
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crystallographic (Strater et a l ,  1995) and EXAFS values (Priggemeyer et a l ,  1995; Sift et al.,
1999) for the Zn-Fe distance in purple acid phosphatase.
It was also considered of interest to see if any deviation of the Zn from the plane of the 
imidazole ring could be detected by EXAFS, as theoretical simulations (Pettifer et al., 1986) have 
shown that such deviations can have large effects, in particular on the intensity of the feature at just 
above 4 A in the Fourier transform. In the Zn imidazole compounds included in this study, such 
deviations are also present, but only 5, where the Zn is 0.44 A out of the imidazole plane, lends 
itself to a more detailed investigation, as for the other compounds the deviations are smaller and the 
differences between the imidazole units are too large (0.02 and 0.18 A for 3, 0.11 and 0.23 A for 4). 
Our simulations (not shown) confirm that moving the Zn out of the imidazole plane lowers the 
intensity of the features at 4 A. Work to discriminate in the approach for the refinement of the 
simulation between this effect and other effects that affect the intensity, like the value of the 
Debye-Waller-type factor, is still in progress; no further attempts were made, however, to interpret 
the integrase data in this respect.
Conclusions and Outlook
We find that the XANES and EXAFS measurements provide independent evidence for the 
information that was put into the NMR structure (Eijkelenboom et al., 1997; Eijkelenboom et al.,
2000), viz. four-coordinated zinc with 2 N (imidazole) and 2 S (sulfur) at 2.0 and 2.3 A, 
respectively, and that the coordination chemistry derived from the NMR structure has a solid 
foundation. The reagent P-mercaptoethanol, which was present during the NMR structure 
determination, has a small but significant effect on the EXAFS, but the only parameters changed in 
the analysis are some of the Debye-Waller-type factors, and the validity of the structure derived by 
NMR is not affected.
We have shown that the N and S contributions in a system like the Zn site in integrase can 
be resolved by taking the Fourier transform over a larger range of data than is typically analysed, 
allowing an estimate of their relative sizes. In addition, we have developed a protocol for the 
analysis of the EXAFS of Zn imidazole complexes, in which independent evidence for the 
orientation of the imidazoles with respect to the Zn-N vector is obtained, along with correct 
predictions for the distances of any non-imidazole ligands involved. The possibilities to analyse the 
effect on the EXAFS of lifting the metal ion out of the imidazole plane, and to obtain information 
on metal-imidazole interactions generally from XANES simulations should be explored in further 
work.
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Provided that they can be carried out on a much smaller amount of protein than is possible 
nowadays, and much more readily and confidently interpreted than has been possible in the past, 
EXAFS studies can help identify the ligand environment in metalloproteins and provide a relatively 
simple experimental check for a predicted/proposed metal site. The efforts of the biological EXAFS 
(BIOXAS) community to continue to develop improved sources and detectors so that reliable XAS 
(EXAFS) measurements are possible for even smaller and more diluted samples, and to develop 
procedures for simulation and protocols for the analysis in order to extract information reliably 
deserve support at all levels. The development of protocols for the analysis and their validation on 
model compounds are expected to be important if the measurement and interpretation of XAS 
spectra of proteins are to play a role in high-throughput screening of metalloproteins in structural 
genomics programmes in the post-genomic era. It can be envisaged that it will be possible to 
identify potential metal-coordinating sites in the genetic information that is now rapidly becoming 
available; obviously in order for XAS to be of use on such studies, a satisfactory solution will have 
to be found for the problem of expression of a potential metalloprotein with incorporation of the 
biologically relevant metal, which, along with attachment of carbohydrate chains, modification of 
amino acids, incorporation of organic cofactors, and self-assembly into functional non-covalently 
bound protein aggregates, is an important post-transcriptional event.
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Table 1. Classification of Zn-sites in proteins by EXAFS and/or crystallography, adapted from 
(Garner & Feiters, 1987; Hasnain & Garner, 1987; Feiters, 1990).
Type Characteristic Examples
A S ligands only LADH “structural” (Eklund et al., 1976; Zeppezauer et al., 1986) 
Metallothionein (Abrahams et al., 1986)
Ada protein (Myers et al., 1993)
Neuronal growth inhibiting factor (Bogumil et al., 1998)
B N/O and S ligands LADH “catalytic” (Eklund et al., 1976)
Sorbitol dehydrogenase
(Eklund et al., 1985; Feiters & Jeffery, 1989)
Transcription factor (Diakun et al., 1986)
Nucleocapsid zinc finger (Summers et al., 1992)
Methionine synthase
(González et al., 1996; Peariso et al., 1998; Zhou et al., 1999) 
Methyl transferase (Gencic et al., 2001; Krüer et al., 2002)
Spinach carbonic anhydrase (Bracey et al., 1994)
C N/O ligands only Carbonic anhydrase (Liljas et al., 1972; Yachandra et al., 1983) 
Methanosarcina carbonic anhydrase (Alber et al., 1999)
Thermolysin (Colman et al., 1972)
Superoxide dismutase
(Richardson et al., 1975; Blackburn et al., 1983; Murphy et al., 1996) 
Carboxypeptidase (Rees et al., 1981)
Zn-containing ferredoxin (Cosper et al., 1999)
Fe(III)-Zn(II) purple acid phosphatase
(Priggemeyer et al., 1995; Sträter et al., 1995; Klabunde et al., 1996)
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Table 2. Parameters for the final simulations of the EXAFS (Fig. 4) and comparison with 
crystallographic values for zinc(II) ethylxanthate 1 and zinc(II) dimethyldithiocarbamate 2. 
Amplitude reduction factor, 0.75; imaginary potential, -1 V; energy range, 25 - 730 eV.
Zn(II) ethylxanthate 1 (Fig. 4a)
EXAFS crystala
Type occupancy, distance occupancy,
distance
Zn(II) dimethyldithiocarbamate 2 (Fig. 4b). 
EXAFS crystalb
occupancy, distance occupancy,
distance
S 3.6 at 2.341 À (0.005) c 4 at 2.36 À
C 1.7 at 3.171 À (0.004) c 4 at 3.21 À
S 1.0 at 3.417 À (0.005) c 4 at 3.46 À 
S - - 
ÀE0 9.48 eV 
Fit index 0.00050
4.2 at 2.346 À (0.008) c 4 at 2.36 À
1.2 at 2.960 À (0.030) c 1 at 3.04 À
1.8 at 4.197 À (0.014) c 1 at 4.27 À
10.33 eV 
0.00036
a) crystal structure of 1from Ikeda & Hagihara, 1966.
b) crystal structure of 2 from Klug, 1966.
c) Debye-Waller-type factors, quoted as 2a2 (À2), in parentheses.
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Table 3. Parameters for the simulations of the EXAFS (Fig. 5) and comparison with 
crystallographic values for Zn imidazole compounds. Amplitude reduction factor, 0.75; imaginary 
potential, -1 V.
[Zn(im)4](ClO4)2 (3, Fig. 5a) Zn(im)2(acetate)2  (4, Fig. 5b) [Zn(his)2 ](H2O)2  (5, Fig. 5c)
Type EXAFS Xtala EXAFS Xtalb EXAFS Xtalc
No of Im 
N(im)
Rd, ae 
C(im)
Rd, ae 
f
angle
C(im)
Rd, ae 
f
angle
N(im)
Rd, ae 
f
angle
C(im)
Rd, ae 
f
angle
4 4
1.972, 0.000 2.000
2.928, 0.005 3.002
- 124.30 - 126.03
3.019, 0.005 3.037
126.59 126.01
4.060, 0.006 4.149
- 163.20 - 161.54
4.220, 0.006 4.182
160.88 161.63
1.995, 0.004 1.999
2.930, 0.007 2.940
- 121.62 - 123.35
3.080, 0.007 3.074
132.91 130.38
4.070, 0.009 4.098
- 158.88 - 157.71
4.237, 0.009 4.176
165.60 164.50
1.990, 0.008 2.039
3.007, 0.014 3.029
- 128.36 - 130.50
2.929, 0.014 3.003
120.21 120.30
4.144, 0.023 4.098
- 165.97 - 159.36
4.133, 0.023 4.108
157.46 153.41
Rd, ae
2 O(acetate)
1.940, 0.004 1.973
2 N(amino)
2.054, 0.008 2.061
Energy range 2.4 -  755 eV
ÀE0 12.84 eV
Fit index 0.00034 (0.00131)g
2.4 -  985 eV 
13.16 eV
0.00021 (0.00084)g
2.4 -  755 eV 
13.58 eV g 
0.00039 (0.00151)g
a) Crystallographic values for 3 from Bear et al., 1975, cf. Fig. 3.
b) Crystallographic values for 4 from Horrocks et al., 1982.
c) Crystallographic values for 5 from Kretsinger et al., 1963.
d) R, distance to absorber Zn atom in À.
e) a, Debye-Waller-type factor, quoted as 2a2 (À2).
f) angle with respect to Zn-N, positive values correspond to upper halves of imidazoles in Fig. 3. 
g) values without restraints in parentheses.
2 2 2 2
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Table 4. Parameters for the final simulations of the EXAFS (Fig. 6) of Zn in the N-terminal part of 
HIV integrase-2 N. Amplitude reduction factor, 0.75; imaginary potential, -1 V.
with P-mercaptoethanol (Fig.6a) without P-mercaptoethanol (Fig.6b)
energy range, 2.6 - 700 eV energy range, 2.6 - 735 eV
Type occupancy, distance angle with occupancy, distance angle with
respect to Zn-Na respect to Zn-N
S 2 at 2.263 À (0.007) b 2 at 2.264 À (0.009) b
N (im) 2 at 1.984 À (0.005) b 2 at 1.989 À (0.005) b
C (im) 2 at 2.979 À (0.022) b - 125.63 a 2 at 2.797 À (0.020) b - 125.59 a
C (im) 2 at 3.025 À (0.022) b + 126.38 a 2 at 3.013 À (0.020) b + 125.45
N (im) 2 at 4.135 À (0.033) b - 161.60 a 2 at 4.130 À (0.033) b - 162.03 a
C (im) 2 at 4.169 À (0.033) b + 162.49 a 2 at 4.163 À (0.033) b + 161.85 a
AEc 14.84 eV 14.68 eV
Fit index 0.00022 (0.00090) c 0.00018 (0.00073) c
a
a
a) positive values correspond to upper halves of imidazoles in Fig. 3.
b) Debye-Waller-type factors, quoted as 2a2, in parentheses.
c) values without restraints in parentheses.
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Table 5. Dependence of fit index (* 103, corrected for offset due to restraints) of EXAFS 
simulations of integrase on S and N(im) occupancies.
Total Coordination
Number: 2 3 4 5 6
with P-mercaptoethanol
0 N 4 S 214
1 N + 1 S 177 a,b + 2 S 118 a + 3 S 112 + 4 S 128
2 N + 1 S 119 b + 2 S 89 + 3 S 100 + 4 S 119
3 N + 1 S 109 + 2 S 93 + 3 S 104
4 N + 0 S 383 + 1 S 124 + 2 S 112
without P-mercaptoethanol
0 N 4 S 212
1 N + 1 S 187 a + 2 S 114 a + 3 S 101 + 4 S 111
2 N + 1 S 113 + 2 S 73 + 3 S 79 + 4 S 94
3 N + 1 S 97 + 2 S 75 + 3 S 80
4 N + 0 S 340 + 1 S 111 + 2 S 92
a) Debye-Waller type factor for coordinating nitrogen refines to negative value.
b) Debye-Waller type factor for sulfur refines to negative value.
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Figure Legends
Figure 1. XANES (top panel, E0 = 9660 eV), k3-weighted EXAFS (middle panel), and modulus of 
phase-corrected Fourier transform (bottom panel) of 4 model compounds and 2 protein samples, 
viz. (top to bottom) Zn ethylxanthate 1; Zn dimethyldithiocarbamate 2; integrase with P- 
mercaptoethanol; integrase; [Zn(imidazole)4](ClO4)2 3; Zn(imidazole)2(acetate)2 4.
Figure 2. Comparison of N-terminal part of HIV integrase-2 with (dashed line) and without (solid 
line) P-mercaptoethanol; top panel, extended range (k 2-16 Á-1) of k2-weighted EXAFS; bottom 
panel, corresponding modulus of the phase-corrected Fourier transform.
Figure 3. Averaged geometry of the two types of imidazole coordinating to zinc(II) in 
[Zn(imidazole)4](ClO4)2 3 (Bear et a l ,  1975), showing the restraints used in the refinement of the 
EXAFS data. Bold, so-called ‘single’ restraints used in all refinements; italic, optional 
‘double’restraints; in parentheses, distance values that were refined in the iteration.
Figure 4. k3-weighted EXAFS (top panels) and modulus of phase-corrected Fourier transform 
(bottom panels) of experimental (solid lines) and simulations (dashed lines, parameters in Table 2) 
of (left) zinc(II) ethylxanthate 1 and (right) Zn(II) dimethyldithiocarbamate 2.
Figure 5. k3-weighted EXAFS (top panels) and modulus of phase-corrected Fourier transform 
(bottom panels) of experimental (solid lines) and simulations (dashed lines, parameters in Table 3) 
of [Zn(imidazole)4](ClO4)2 3, Zn(imidazole)2(acetate)2 4, and di-(L-histidino)-zinc(II) dihydrate 5. 
Insets of bottom panels: final geometry of imidazole ring after refinement, with Zn as the central 
atom, nitrogen atoms (1) and (4), and carbon atoms (2), (3), and (5).
Figure 6. k3-weighted EXAFS (top panels) and modulus of phase-corrected Fourier transform 
(bottom panels) of experimental (solid lines) and simulations (dashed lines, parameters in Table 4) 
of the N-terminal part of HIV-II integrase-2 with (left) and without (right) P-mercaptoethanol. 
Insets of bottom panels: final geometry of imidazole ring after refinement, with Zn as the central 
atom, nitrogen atoms (1) and (4), and carbon atoms (2), (3), and (5).
Figure 7. Coordination topology of the zinc center in the N-terminal domain of HIV-2 integrase, 
proposed in the NMR study (Eijkelenboom et al., 1997) and confirmed by the present EXAFS 
results.
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